Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Experience with citicoline in patients with post-stroke cognitive impairment

https://doi.org/10.14412/2074-2711-2020-4-43-48

Full Text:

Abstract

Objective: to investigate the efficacy and safety of citicoline (Ceresil® Canon) in patients with post-stroke cognitive impairment.

Patients and methods. Examinations were made in 33 patients aged 45 years and older who had experienced primary ischemic hemispheric stroke with complaints of a decline in memory or other cognitive functions. The cognitive status was assessed using the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA). The presence of anxiety-depressive spectrum disorders was determined on the Hospital Anxiety and Depression Scale. All the patients received citicoline (Ceresil® Canon) oral solution at a dose of 1000 mg/day for 3 months.

Results and discussion. Citicoline administration showed a statistically significant reduction in the severity of cognitive impairment (p<0.001). The time course of positive changes in the cognitive status of patients was reflected by an increase in the median score on the MMSE from 26 [25; 27.5] to 28 [26.5; 29] and on MoCA from 23 [21; 25] to 25 [22; 26]. There was a decline in the number of patients with anxiety-depressive disorders. No adverse events or side effects were found in the patients.

Conclusion. The findings suggest that citicoline (Ceresil® Canon) produced as an oral solution is well tolerated and improves cognitive functions and affective sphere in patients in the recovery period of ischemic stroke.

About the Authors

A. N. Bogolepova
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; Federal Center for the Brain and Neurotechnologies, Federal Biomedical Agency of Russia
Russian Federation

Anna Nikolaevna Bogolepova

1, Ostrovityanov St., Build. 10, Moscow 117997
1, Ostrovityanov St., Moscow 117997 



S. G. Burd
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; Federal Center for the Brain and Neurotechnologies, Federal Biomedical Agency of Russia
Russian Federation
1, Ostrovityanov St., Build. 10, Moscow 117997
1, Ostrovityanov St., Moscow 117997


A. V. Lebedeva
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; Research Institute for Health Care and Medical Management, Moscow Healthcare Department
Russian Federation
1, Ostrovityanov St., Build. 10, Moscow 117997
9, Sharikopodshipnikovskaya St., Moscow 115088


E. A. Kovalenko
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; Federal Center for the Brain and Neurotechnologies, Federal Biomedical Agency of Russia
Russian Federation
1, Ostrovityanov St., Build. 10, Moscow 117997
1, Ostrovityanov St., Moscow 117997


References

1. Krishnamurthi RV, Ikeda T, Feigin VL. Global, regional and country-specific burden of ischaemic stroke, intracerebral haemorrhage and subarachnoid haemorrhage: a systematic analysis of the global burden of disease study 2017. Neuroepidemiology. 2020;54(2):171-9. doi: 10.1159/000506396

2. Gusev EI, Martynov MYu, Kamchatnov PR. Ischemic Stroke: Current Status. Doktor.ru. 2013;5(83):7-12 (In Russ.).

3. GBD 2016 Stroke Collaborators. Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(5):439-58. doi: 10.1016/S14744422(19)30034-1

4. Kovalenko EA, Bogolepova AN, Katunin DA. The role of pre-stroke cognitive disorders in the formation of post-stroke cognitive. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2017;117(12-2):19-24. doi: 10.17116/jnevro201711712219-24 (In Russ.).

5. Cherdak MA, Jahno NN. Neurodegenerative and vascular factors of poststroke cognitive impairment. Nevrologicheskij zhurnal. 2012;5(17):10-5. doi: 10.18821/1560-95452012-17-5-10-15 (In Russ.).

6. Gutierrez Perez C, Savborg M, Pahlman U, et al. High frequency of cognitive dysfunction before stroke among older people. Int J Geriatr Psych. 2011;26(6):622-9. doi: 10.10.1002/gps.2573

7. Qu Y, Zhuo L, Li N, et al. Prevalence of post-stroke cognitive impairment in china: a community-based, cross-sectional study. PLoS One. 2015;10(4):1-15. doi: 10.1371/journal.pone.0122864

8. Bogolepova AN. Vascular depression and cognitive dysfunction. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2019;11(Suppl. 3):26-31. doi: 10.14412/2074-2711-2019-3S-26-31 (In Russ.).

9. Secades JJ. Citicoline in the treatment of cognitive impairment. J Neurol Exper Neurosci. 2019;5(1):14-26. doi: 10.17756/jnen.2019-047

10. Parfenov VA. Citicolin in the treatment of stroke and vascular cognitive disorders. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2009;1(3-4):69-74. doi: 10.14412/2074-27112009-59 (In Russ.).

11. Hurtado O, Cardenas A, Pradillo JM, et al. A chronic treatment with CDP-choline improves functional recovery and increases neuronal plasticity after experimental stroke. Neurobiol Dis. 2007;26(1):105-11. doi: 10.1016/j.nbd.2006.12.005

12. Singh M, Khan MI, Giri R, Kumar L. Role of citicoline in improvement of cognition, memory and post stroke disability in stroke patients. Int J Advances Med. 2019;6(2):429. doi: 10.18203/2349-3933.ijam20191154

13. Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev. 2005;18(2):CD000269. doi: 10.1002/14651858.CD000269.pub2

14. Mushba AV, Ivanova DS, Vinogradov OI. Assessing the impact of citicoline on the efficiency of rehabilitation measures in patients with ischemic stroke. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2016;116(2):71-5. doi: 10.17116/jnevro20161162171-75 (In Russ.).

15. Mashin VV, Belova LA, Bahtogarimov IR, et al. Multicenter observational program for evaluation of the effectiveness of the recognan (citicoline) in the correction of cognitive impairment in patients with chronic cerebrovascular pathology. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2017;117(8):39-43. doi: 10.17116/jnevro20171178139-43 (In Russ.).

16. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-98. doi: 10.1016/0022-3956(75)90026-6

17. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Amer Geriatr Soc. 2005;53(4):695-9. doi: 10.1111/j.1532-5415.2005.53221.x

18. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361-70. doi: 10.1111/j.16000447.1983.tb09716.x

19. Verbickaja SV, Parfenov VA, Reshetnikov VA, et al. Post-stroke cognitive impairment (results of a 5-year follow-up). Nevrologiya, neyropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2018;10(1):37-42. doi: 10.14412/2074-2711-2018-1-37-42 (In Russ.).

20. Kovalenko EA, Bogolepova AN. Dynamics of poststroke cognitive deficiency and the main factors influencing it. Farmateka. 2018;(5):4652. doi: 10.18565/pharmateca.2018.5.46-52 (In Russ.).

21. Alvarez-Sabin J, Santamarina E, Maisterra O, et al. Long-term treatment with citicoline prevents cognitive decline and predicts a better quality of life after a first ischemic stroke. Int J Mol Sci. 2016;17(3):390. doi: 10.3390/ijms17030390

22. Cotroneo AM, Castagna A, Putignano S, et al. Effectiveness and safety of citicoline in mild vascular cognitive impairment: the IDEALE study. Clin Intervent Aging. 2013;8:131. doi: 10.2147/CIA.S38420

23. Аlvarez-Sabin J, Roman GC. Citicoline in vascular cognitive impairment and vascular dementia after stroke. Stroke. 2011;42(suppl 1):40-3. doi: 10.1161/STROKEAHA.110.606509

24. Bogolepova AN. Pathogenetic approaches to treatment of chronic cerebrovascular insufficiency. Nervnye bolezni. 2019;(3):16-21. doi: 10.24411/2226-0757-2019-12120 (In Russ.).

25. Barbagallo SG, Barbagallo M, Giordano M, et al. Alpha-glycerophosphocholine in the mental recovery of cerebral ischemic attacks. An Italian multicenter clinical trial. Ann NY Acad Sci. 1994;717:253-69. doi: 10.1111/j.17496632.1994.tb12095.x

26. Parnetti L, Amenta F, Gallai V. Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data. Mechan Ageing Developm. 2001;122(16):2041-55. doi: 10.1016/S00476374(01)00312-8


For citation:


Bogolepova A.N., Burd S.G., Lebedeva A.V., Kovalenko E.A. Experience with citicoline in patients with post-stroke cognitive impairment. Neurology, Neuropsychiatry, Psychosomatics. 2020;12(4):43-48. (In Russ.) https://doi.org/10.14412/2074-2711-2020-4-43-48

Views: 78


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)